Vaginal Progesterone Effects on Ultrasound Indices, Fetal Outcomes, and Preeclampsia in High-risk Pregnancy : Vaginal Progesterone in High-risk Pregnancy: Ultrasound Indices and Outcomes

阴道孕酮对高危妊娠超声指标、胎儿结局和先兆子痫的影响:高危妊娠中的阴道孕酮:超声指标和结局

阅读:1

Abstract

BACKGROUND: According to the high prevalence and importance of preeclampsia and its relationship with uterine artery resistance, the purpose of this study was to determine the effect of vaginal progesterone administration on ultrasound indices, fetal outcomes, and high-risk women pregnancy in terms of the incidence of preeclampsia. MATERIALS AND METHODS: In this randomized, double-blind clinical trial, the number of 60 pregnant women between 11 to 14 weeks with risk factors for preeclampsia were examined according to the inclusion criteria and based on random assignation method in two groups of 30 patients (intervention group: 80 mg aspirin tablets + 400 mg vaginal progesterone suppositories and control group: 80 mg aspirin tablets) based on maternal and fetal outcomes and uterine artery color Doppler ultrasound (pulsatility index (PI) and vascular resistance index (RI). RESULTS: The prevalence of preterm birth in the intervention group was lower significantly difference (P≤0.05). In the intervention group, uterine artery PI after the study had a greater decrease than before the study on the right side (0.33±0.42 vs. 0.05±0.28, P≤0.05) and on the left side (0.38±0.49 vs. 0.09±0.2, P≤0.05), compared to the control group. In the intervention group, uterine artery RI after the study had a greater decrease than before the study on the right side (0.20±0.31 vs. 0.02±0.10, P≤0.05) and on the left side (0.22±0.3 vs. 0.03 ± 0.1, P≤0.05), compared to the control group. CONCLUSION: Progesterone suppositories in addition to aspirin, can reduce the prevalence of preterm birth and uterine artery PI and RI values.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。